| 11.41 0.22 (1.97%) | 10-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.97  |
1-year : | 15.46 |
| Resists | First : | 11.96 |
Second : | 13.23 |
| Pivot price | 11.04 |
|||
| Supports | First : | 9.89 | Second : | 8.23 |
| MAs | MA(5) : | 11.02  |
MA(20) : | 11.3 |
| MA(100) : | 12.81 |
MA(250) : | 12.3 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 54.4 |
D(3) : | 46.2 |
| RSI | RSI(14): 48.2 |
|||
| 52-week | High : | 17.79 | Low : | 8.07 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ENTA ] has closed below upper band by 30.7%. Bollinger Bands are 30.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.5 - 11.55 | 11.55 - 11.59 |
| Low: | 10.93 - 10.99 | 10.99 - 11.03 |
| Close: | 11.31 - 11.4 | 11.4 - 11.48 |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Sat, 05 Oct 2024
Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt? - Simply Wall St
Fri, 04 Oct 2024
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains? - MSN
Wed, 02 Oct 2024
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains? - Yahoo Finance
Fri, 27 Sep 2024
Enanta Pharmaceuticals (NASDAQ:ENTA) Rating Reiterated by JMP Securities - MarketBeat
Thu, 26 Sep 2024
Enanta Pharmaceuticals Reports Antiviral For Respiratory Syncytial Virus Reduces Virus Levels, Symptoms In Study - Benzinga
Thu, 26 Sep 2024
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Armistice Capital LLC - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 21 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 6 (%) |
| Held by Institutions | 104.5 (%) |
| Shares Short | 2,920 (K) |
| Shares Short P.Month | 2,960 (K) |
| EPS | -5.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.03 |
| Profit Margin | -160.3 % |
| Operating Margin | -134.6 % |
| Return on Assets (ttm) | -17.2 % |
| Return on Equity (ttm) | -59.7 % |
| Qtrly Rev. Growth | -5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.39 |
| EBITDA (p.s.) | -5.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -90 (M) |
| Levered Free Cash Flow | -63 (M) |
| PE Ratio | -2.1 |
| PEG Ratio | 0 |
| Price to Book value | 1.62 |
| Price to Sales | 3.35 |
| Price to Cash Flow | -2.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|